ADDENDUM – Influvac® Use in Children
ADDENDUM – Influvac® Use in Children
Advisory Committee Statement (ACS)
National Advisory Committee on Immunization (NACI)
The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization. PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.
This addendum to the Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017–2018 has been issued to address updated recommendations regarding the use of the Influvac® trivalent inactivated influenza vaccine in children 3–17 years of age.
NACI recommendation: Use of Influvac® trivalent inactivated influenza vaccine in children
The recent authorization by Health Canada, extending the indication for the use of Influvac® (BGP Pharma ULC) to include children 3–17 years of age, provided the impetus for NACI to review the recommendation on the use of the vaccine. After careful review of available evidence, NACI has revised its recommendation on the use of Influvac®, a trivalent inactivated influenza vaccine (TIV):
NACI recommends that Influvac® should be considered among the TIVs offered to children 3–17 years of age when a quadrivalent influenza vaccine is not available (Strong NACI Recommendation).
NACI concludes that there is fair evidence of vaccine effectiveness, immunogenicity and safety to recommend the use of Influvac® for children 3–17 years of age (Grade B Evidence). There is insufficient evidence, in quantity and quality, to recommend the use of Influvac® for children younger than three years of age (Grade I Evidence). The recommendation on the use of Influvac® in children is a change from previous NACI statements, as Influvac® was not previously recommended by NACI for use in persons younger than 18 years of age.
Notwithstanding this new recommendation on the use of Influvac® (a TIV), NACI continues to recommend that a quadrivalent formulation of influenza vaccine be used for children younger than 18 years of age. If a quadrivalent vaccine is not available, a TIV should be used.
For complete prescribing information, readers should consult the product leaflets or information contained within the authorized product monographs available through Health Canada’s Drug Product Database.
The full-text of this publication is not available in HTML format at this time. Please email NACI-CCNI@hc-sc.gc.ca to obtain a Portable Document Format (PDF) copy of the NACI "Addendum – Influvac® Use in Children: Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017-2018" publication. If an accessible version is needed please specify the desired format in the email message.
Report a problem or mistake on this page
- Date modified: